WED-141 Patients with compensated MASH cirrhosis and Fibroscan® VCTE score <15 kPa: baseline data from a phase 3 double-blinded randomized clinical trial assessing the safety and efficacy of pegozafermin (ENLIGHTEN-Cirrhosis)

作者：Rohit Loomba, Naim Alkhouri, Quentin M. Anstee, Hank Mansbach, Cynthia L. Hartsfield, Laura Contreras, Jasmine Dowlat, Jennifer B Kang, Shibao Feng, Maya Margalit · 发表于：Journal of Hepatology · 年份：2026 · DOI：10.1016/s0168-8278(26)01683-1 · 研究领域：Liver Disease and Transplantation、Liver Disease Diagnosis and Treatment、Silymarin and Mushroom Poisoning